Ash Access Technology, Inc. is an integrated specialty pharmaceutical / medical device company engaged in the development and commercialization of proprietary technologies and devices to treat and prevent the clinical consequences of diseases and disorders related to vascular access. The company has an advanced portfolio of innovative products targeting catheter-related bloodstream infections (CRBSI) and poor patency (blood flow) – the significant challenges associated with the use of both acute and chronic catheters for vascular access.

The company was founded in 2003 by Mr. Robert B.Truitt (President & CEO) and Dr. Stephen R. Ash (Chaiman of the Board) in Lafayette, IN. Our research and development programs are led by the expertise and practical experience of Dr. Ash who has been a practicing nephrologist for over 30 years. Dr. Ash is a world-recognized researcher and thought-leader in the field of Nephrology / Interventional Nephrology; patent holder in extracorporeal devices, sorbent chemistry, and vascular / peritoneal access devices; and a founding member of the ASDIN (American Society of Diagnostic & Interventional Nephrology).

Our team’s comprehensive understanding of vascular access devices, their complications and clinical consequences, combined with the proven ability for product development and commercialization, creates an organization that is well positioned to make a unique and significant impact in the lives of patients suffering from the consequences of vascular access complications. We are building our commercial product portfolio to focus on breakthrough technologies in areas with significant, unmet medical needs:

• Discovering, formulating, clinical testing and commercializing a novel antimicrobial / antithrombotic therapy (Zuragen™) for the prevention and treatment of CRBSI as well as the eradication of biofilm.
• Building a dynamic hemodialysis and peritoneal dialysis catheter portfolio that includes an innovative curved tip design and other technological advances which provide significant differences from current catheters on the market.
• Pursuing the integration of Zuragen™ technology with our catheter designs to form a novel eluting device that creates a barrier for infection which would potentially last months instead of days.

The commitment to fulfill our mission is also evident by the substantial investment in our ongoing research and development programs, established partnerships with industry leading research organizations as well as our collaboration with thought-leaders and experts in the fields of Nephrology, Interventional Nephrology and Infectious Disease.